Rituximab and Hyaluronidase Human
This page contains brief information about rituximab and hyaluronidase human and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Rituximab and hyaluronidase human is approved to be used alone or with other drugs to treat:
- Chronic lymphocytic leukemia (CLL). It is used with fludarabine and cyclophosphamide.
- Diffuse large B-cell lymphoma. It is used with anthracycline chemotherapy in patients whose disease has not been treated.
- Follicular lymphoma. It is used in follicular lymphoma that:
Rituximab and hyaluronidase human is a form of rituximab that is given as a subcutaneous injection. This form can be given more quickly than rituximab, which is given as an infusion. This shortens the amount of time it takes to receive each treatment. The subcutaneous form is used only after patients have received one full dose of rituximab by infusion. For more information about rituximab that may apply to rituximab and hyaluronidase human, see the Drug Information Summary for Rituximab.
More About Rituximab and Hyaluronidase Human
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Rituximab And Hyaluronidase Human - Check for trials from NCI's list of cancer clinical trials now accepting patients.